Antibody delivery technology enhances immunotherapy for glioblastoma and suppresses side effects

These results were published in the journal Nature Biomedical Engineering (IF = 25.

October 6, 2021, Kawasaki (Japan) and the University of Tokyo: Nanomedicine Innovation Center, Kawasaki Industrial Promotion Research Institute (Director: Kazuno Kataoka, location: Kawasaki-ku, Kawasaki City; abbreviated name: Biology with the Graduate School of Engineering, University of Tokyo The engineering department cooperated to successfully inject an immune checkpoint inhibitor (ICI) into the mouse brain with high efficiency, confirming its high efficiency and specificity in the treatment of orthotopic transplantation mice with glioblastoma (GBM) Sex (*1)

Immune checkpoints are a normal part of the immune system, and their role is to prevent the immune response from being too strong and destroying healthy cells in the body

Therefore, the purpose of this study is to develop a technology that can effectively increase the accumulation of ICIs in brain tumors in order to achieve the effectiveness and safety of the treatment

Through the detection of anti-tumor immune cells in Glc-ICI treatment of mouse brain tumors, it was found that the number of natural killer cells (NK) and CD8+ T cells that attack tumors increased, and the m2-like macrophages were effectively repolarized to m1-like macrophages.

(*1) Glioblastoma: A brain tumor that progresses very quickly and has a very poor prognosis.

(*2) "Nature-Biomedical Engineering": A sister journal of the British scientific journal "Nature", it is a leading academic journal in the field of biomedical engineering

(*3) Japanese approved ici: nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), avelumab (anti-PD-L1), atezolizumab (anti-PD-L1), durvalumab (anti-PD -L1), ipilimumab (anti-CTLA-4)

(*4) Avelumab: An immune checkpoint inhibitor developed as a human anti-pd-l1 antibody